Skip to main content

Advertisement

Table 4 Toxicity profiles of AC/SD chemotherapy

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

   NCI-CTC AE grade
Toxicities G1 G2 G3 G4 G5 ≥G3 (%)
Hematologic toxicity (by cycle)       
  Neutropenia 2/1 1/3 6/6 6/9 0/0 12/15 (6.2/8.7)
  Febrile neutropenia 0/0 0/0 6/4 0/1 0/0 6/5 (3.1/2.9)
  Anemia 0/0 0/0 0/1 2/0 0/0 2/1 (1.0/0.6)
Non-hematologic toxicity (by patient)       
  Epigastric pain 7/15 3/2 0/6 0/0 0/0 0/6 (0/12.2)
  Nausea 19/11 8/4 1/2 0/0 0/0 1/2(2.0/4.1)
  Vomiting 8/9 4/3 1/2 0/0 0/0 1/2 (2.0/4.1)
  Stomatitis/mucositis 12/14 2/10 0/2 0/0 0/0 0/2 (0/4.1)
  Infection 0/0 1/1 1/0 0/1 0/1 1/2(2.0/4.1)
  Increased ALT 0/0 0/2 1/2 0/0 0/0 1/2 (2.0/4.1)
  Myalgia 6/13 1/7 0/1 0/0 0/0 0/1 (0/2.0)
  Diarrhea 2/4 2/2 0/1 0/0 0/0 0/1 (0/2.0)
  Hand-foot syndrome 0/1 0/3 0/1 0/0 0/0 0/1 (0/2.0)
  Anorexia 18/10 3/9 0/0 0/0 0/0 0/0 (0/0)
  Constipation 9/8 1/7 0/0 0/0 0/0 0/0 (0/0)
  Arthralgia 1/2 1/3 0/0 0/0 0/0 0/0 (0/0)
  Peripheral neuropathy 2/6 0/3 0/0 0/0 0/0 0/0 (0/0)
  Edema 1/9 0/1 0/0 0/0 0/0 0/0 (0/0)
  Fatigue 16/0 0/1 0/0 0/0 0/0 0/0 (0/0)
  1. NCI-CTC AE, National Cancer Institute-Common Terminology Criteria for Adverse Events. Total number of cycles delivered was 193/172 cycles for AC/SD.